SEATTLE, April  24, 2026  (GLOBE NEWSWIRE) --  Perspective Therapeutics, Inc. (&#34;Perspective&#34; or the &#34;Company&#34;) (NYSE:CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout

CATX

Perspective Therapeutics to Provide Several Upcoming Corporate Updates

CATX to Share Key Updates and Financial Results in May 2026

<section class="insight" data-version="1">
 <section data-block="information">
 <h3>Information</h3>
 SEATTLE, April 24, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (&amp;#34;Perspective&amp;#34; or the &amp;#34;Company&amp;#34;) (NYSE:CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout
 </section>

 <section data-block="ai-summary-paragraph">
 <h3>AI Summary</h3>
 Perspective Therapeutics (CATX) will host an analyst event and release quarterly financial results in May 2026, which could influence investor sentiment. Upcoming conferences and webcasts may provide important insights into the company&#039;s pipeline and financial health.
 </section>

 <section data-block="ai-summary-bullets">
 <h3>Key Points</h3>
 <ul><li>CATX announces corporate updates planned for May 2026.</li><li>Key events include an analyst strategy webcast on May 4.</li><li>First quarter financial results due after market close on May 11.</li><li>Participation in healthcare conferences on May 13 and 19.</li></ul>
 </section>

 <section data-block="companies-mentioned">
 <h3>Companies Mentioned</h3>
 <ul><li>Perspective Therapeutics, Inc. (CATX): Company&#039;s upcoming events may affect stock price positively or negatively.</li></ul>
 </section>

 <section data-block="category">
 <h3>Corporate Developments</h3>
 This falls under Corporate Developments as the scheduling of events and financial disclosures typically shapes market expectations and investment behavior, particularly in biotech.
 </section>

 <section data-block="market-moving">
 <h3>Market-Moving</h3>
 <ul><li>CATX&#039;s webcast on May 4 may raise investor interest in its pipeline.</li><li>Quarterly results on May 11 could affect valuation metrics.</li><li>Participation in major healthcare conferences may enhance visibility and investor confidence.</li></ul>
 </section>

 <section data-block="key-facts">
 <h3>Key Facts</h3>
 <ul><li>Analyst event on May 4 at 8:30 AM ET.</li><li>First quarter results on May 11 after market close.</li><li>BofA Securities fireside chat on May 13.</li><li>RBC Capital Markets conference on May 19.</li></ul>
 </section>

 <section data-block="trading-thesis">
 <h3>Trading Thesis</h3>
 Consider accumulating CATX shares ahead of potential positive price movement from upcoming updates.
 </section>
</section>


<link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css"></link>SEATTLE, April 24, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=-c4C1pPBmZHNAEkO-zFPxseB4CGpEUD-QeF1M3116E5fUH1JQ_Yeu7Z9lA2DtphyJHcC4JUOJXGJy1L8BmrJtXC2HduCJGgw2D6rvvGnlMiO4vN-ArUIjl37Ajm86Snv" rel="nofollow" target="_blank">Perspective Therapeutics, Inc.</a> ("Perspective" or the "Company") (NYSE:<a class="ticker" href="https://www.benzinga.com/quote/CATX">CATX</a>), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that it will provide several corporate updates in May 2026. Webcasts of these events, unless noted as press release only, will be posted on the Company&#39;s website at <a href="https://www.globenewswire.com/Tracker?data=x22gVImKmTnoamvVRJuPwiNqBComUKBSk8WX11ryhqMyiCvwjLFTlrK_PdVYoN8SlpQ935u6YDA4PnWTVSNJkBPp6hAnrxKXi9OAx8KLtRxOaQEAXIVKrDxDufZLJgrO743o8RkV-YruRF9cgpjzjA==" rel="nofollow" target="_blank">www.perspectivetherapeutics.com</a>. Analyst Event on Perspective's Strategy, Enabling Technology, and Pipeline Additional details are available <a href="https://www.globenewswire.com/Tracker?data=l3iGGnE1I7W32ilNWWMn2mj3UQm5cyDr_N-tqufs6l-1VppQjdiUBS5qwkDsd2iXmeZ19uspJ6yPDFLsiwO2HEjRAaHGc8E_wvEWmyfdNLg=" rel="nofollow" target="_blank">here</a>. Date: May 4, 2026 Time: 8:30 a.m. ET First Quarter 2026 Financial Results – Press Release Only The press release will be available on the newsroom section of the Company&#39;s website at <a href="https://www.globenewswire.com/Tracker?data=IptJOmQZuifj8KV-h3WbMql1pwEL-KdJyVem85cHDsTlmdkIofJyU2IQcAW4unP1yjQ9FXsyne3awL2WEnu0_00Jlke4vJCnUA9s_WnCzfdDJ91r73bF-5-8dXZX8pflPR3Q_gruja636Zj4Tg3R2rdmSfQnwLgY73jcl2kkSPa-j0U6ZlNWK8IBgyocOrSQtGUN0CMbhD9gv0AhekgPJAC5NsDv29POdd7emz1A55nccDTJf52xEdheMcPx8Om75l-4MECavQYwTLwk6v1g_z1j-3XTbgTg_xYkysRMGLFYKvDvYaY_hthm428YkrjfdnPBcJYyCClAkumfPQr3v-zgyxPBilCgTBktD5R7zos0PgTZFp6WyQSRi8HoZ9MIQB_b_ry50ME5aWUtbBv6njNS1fKOysh6UMYv8-SPqs0s-3B9SBnCNpaw1eaZiX631DvdTk9viLIOmN0ZzmAMKg==" rel="nofollow" target="_blank">https://perspectivetherapeutics.com/newsroom/press-releases</a>. Date: May 11, 2026 Time: After the market closes BofA Securities Health Care Conference – Fireside Chat Date: May 13, 2026 Time: 2:20 p.m. PT / 5:20 p.m. ET 2026 RBC Capital Markets Global Healthcare Conference – Fireside Chat Date: May 19, 2026 Time: 2:05 p.m. ET About Perspective Therapeutics, Inc. Perspective Therapeutics, Inc. is a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body. The Company has proprietary technology that utilizes the alpha-emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting moieties. The Company is also developing complementary imaging diagnostics that incorporate the same targeting moieties, which provides the opportunity to personalize treatment and optimize patient outcomes. This &#34;theranostic&#34; approach enables the ability to see the specific tumor and then treat it to potentially improve efficacy and minimize toxicity. The Company&#39;s neuroendocrine tumor (VMT-α-NET), melanoma (VMT01), and solid tumor (PSV359) programs are in Phase 1/2a imaging and therapy trials in the U.S. The Company is growing its regional network of drug product candidate finishing facilities, enabled by its proprietary 212Pb generator, to deliver patient-ready product candidates for clinical trials and commercial operations. For more information, please visit the Company&#39;s website at <a href="https://www.globenewswire.com/Tracker?data=x22gVImKmTnoamvVRJuPwiNqBComUKBSk8WX11ryhqNYoKVWibllL0VxR5BCNrT3QPDnzzdMO82X6wSvXuPKmu7dPq14xq2MS5oAnjGV8DJZT1Qy3Fd73MTBma-13ewUU6BQO2LvqR_veAsmo4JvKwupnnPHRO7twYdmrMHvcQVRkzf41HEAbYYiCCpuYDJzoblAG2kYycrbmd5Cx7-IMBXLJMP38gtBttlGAiOxtKW9ze2SO389nv9F516vc_cvLLlKzY9L2igDO6PwWAFVQEw7UQkt5qZXkRyOg1VeCy9OaffXLjDidCj3FFIf-Nql" rel="nofollow" target="_blank">www.perspectivetherapeutics.com</a>. Safe Harbor Statement This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Statements in this press release that are not statements of historical fact are forward-looking statements. Words such as &#34;may,&#34; &#34;will,&#34; &#34;should,&#34; &#34;expect,&#34; &#34;plan,&#34; &#34;anticipate,&#34; &#34;could,&#34; &#34;intend,&#34; &#34;target,&#34; &#34;project,&#34; &#34;estimate,&#34; &#34;believe,&#34; &#34;predict,&#34; &#34;potential,&#34; or &#34;continue&#34; or the negative of these terms or other similar expressions are intended to identify forward-looking statements, though not all forward-looking statements contain these identifying words. Forward-looking statements in this press release include statements concerning, among other things, the Company's clinical development plans and the expected timing for the release of additional data from its clinical programs; the Company's expectations regarding its interactions with regulatory agencies and the expected timing thereof; and other statements that are not historical fact. The Company may not actually achieve the plans, intentions, or expectations disclosed in the forward-looking statements, and you should not place undue reliance on the forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause the Company&#39;s actual results to differ materially from the results described in or implied by the forward-looking statements. Known risk factors include that the Company's clinical trials may be more costly or take longer to complete than anticipated, or may never be completed, or may not generate results that warrant future development of the tested product candidate; the Company may elect to change its strategy regarding its product candidates and clinical development activities; economic and market conditions may worsen; and risks related to the sufficiency of the Company's cash resources for its future operating expenses and capital expenditures. A more complete discussion of the risks and uncertainties facing the Company appears under the heading "Risk Factors" in the Company's most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission (the "SEC"), in the Company's other filings with the SEC, and in the Company's future reports to be filed with the SEC and available at <a href="http://www.sec.gov" title="www.sec.gov">www.sec.gov</a>. Forward-looking statements contained in this news release are made as of this date. Unless required to do so by law, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. Media and Investor Relations Contact: Annie J. Cheng, CFA ir@perspectivetherapeutics.com <img alt="" class="__GNW8366DE3E__IMG" src="https://www.globenewswire.com/newsroom/ti?nf=OTY5NjQ1MCM3NTU0MjAwIzUwMDAyODY4Mw=="></img> <img alt="" src="https://ml.globenewswire.com/media/ZDQ0NTY1YTgtYTliZC00NmE3LTg3NjMtYmM5NDJjY2YyZjFkLTUwMDAyODY4My0yMDI2LTA0LTI0LWVu/tiny/Perspective-Therapeutics-Inc-.png" referrerpolicy="no-referrer-when-downgrade"></img><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/e8b42463-3d31-441e-8c09-6b88826fe1c6"><img src="https://ml.globenewswire.com/media/e8b42463-3d31-441e-8c09-6b88826fe1c6/small/persp-jpg.jpg" border="0" width="150" height="31" alt="Primary Logo"></img></a>

Perspective Therapeutics (CATX) will host an analyst event and release quarterly financial results in May 2026, which could influence investor sentiment. Upcoming conferences and webcasts may provide important insights into the company's pipeline and financial health.

Perspective Therapeutics to Provide Several Upcoming Corporate Updates

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Corporate Developments

Related News